Gene therapy pioneer ReGenX raises $70.5M to go it alone

After years of lending out its R&D platform, ReGenX Bio is turning its attention to a proprietary pipeline of gene therapies, hauling in a $70.5 million D round to get its top prospects into clinical trials.

Source: www.fiercebiotech.com



Comments are closed.